Introduction
Biofunctionalization of implant surfaces has evolved as important tool for the mediation of implant-cell interactions with the major aim to control protein adsorption, improve bio-and hemocompatibility and allow for selective regulation of cell adhesion and proliferation. Among the numerous reported methods for immobilizing biomolecules to surfaces physical adsorption via van der Waals or electrostatic interactions (Fig. 1a) , physical entrapment within hydrogels (Fig. 1b) and covalent attachment via cleavable or non-cleavable bonds (Fig. 1c) are most commonly used. In dependence of the applied immobilization protocol a short-term and long-term localization of the biomolecule on the implant surface can be achieved [1] . Thus, biofunctionalization can be either used to provide the implant with a drug delivery or a novel surface functionality. However, by the application of biodegradable polymers as implant body, even stable immobilization will lead to release of biomolecules upon implant degradation. Within this context, we show exemplary biofunctionalization strategies of poly(L-lactide) (PLLA) for the shortterm and long-term immobilization of vascular endothelial growth factors (VEGF) and anti-CD34 antibodies (CD34-Ab), respectively. The release of growth factors from the surface is often required to enable efficient stimulation of the implant surrounding, while immobilized antibodies, with the general purpose to catch cells to the implant, are supposed to remain on the surface over the duration of use.
Methods
For modification experiments, planar PLLA samples (Resomer® L210, M w = 280,000 g/mol, Boehringer Ingelheim, Germany) were prepared via dip-coating. Short-term VEGF immobilization to PLLA. The shortterm VEGF (Human VEGF A 165 , Biozol Diagnostica, Germany) immobilization to PLLA was investigated via (a) physical adsorption, (b) physical entrapment within a polyacrylic acid (PAA) hydrogel and (c) covalent attachment via a hydrolysable bond. (a) For physical adsorption, PLLA samples were immersed into 1 mL of a solution of VEGF (2 µg/mL) diluted in 100 mM sodium acetate buffer pH 5.0 for 10 min. After washing in the same buffer, the adsorption was repeated four times. (b) The physical entrapment within a PAA hydrogel was achieved via layer by layer deposition. Therefore, PLLA samples were activated regarding the generation of functional anionic surface groups by an oxygen radio frequency (RF) plasma (Diener electronic GmbH & Co. KG, Germany). Afterwards, samples were dipped for 5 min in poly(L-lysine), 5 min in PAA, 10 min in VEGF and again 5 min in PAA by means of a dipcoater (KSV Nima, Finland) according to [2] . This cycle was repeated five times. (c) For covalent attachment, the PLLA samples were plasma-chemically activated as described above and subsequently silanized with aminopropyltriethoxysilane (APTES) and reacted with N,N-disuccinimidyl carbonate (DSC) and VEGF in accordance to [3] . The time course of VEGF release was determined at 37 °C in phosphate buffered saline (PBS) pH 7.2. Individual samples were immersed in 300 µL elution medium for a total duration of at least 168 h. The elution medium was renewed at periodic intervals. The released concentration of VEGF was measured by means of a Sandwich ELISA (human VEGF ELISA Kit RayBio®, Hölzel Diagnostika, Germany). Long-term biomolecule immobilization to PLLA. Prior to long-term CD34-Ab (mouse IgG1, Biozol Diagnostica, Germany) surface immobilization, PLLA samples were activated by an ammonia plasma and modified with a protein-repelling spacer, while CD34-Ab were oxidized with sodium periodate (Thermo Scientific, USA) according to manufacturer's instructions. Final surface immobilization was then achieved in 300 µL of a 100 ng/mL CD34-Ab solution in PBS for 2 h at 23 ± 2 °C. Reduction of the resulting labile Schiff base intermediate to a chemically stable amide bond was performed by the addition of 3 µL of 5 M sodium cyanoborohydride and incubation for 16 h. In order to estimate the stability of the modification at 37 °C in PBS, the CD34-Ab surface density was evaluated after periodic intervals up to 168 h by means of a direct ELISA using a horseradish peroxidase-conjugated secondary antibody (goat anti-mouse, Jackson ImmunoResearch, UK). The amount of CD34-release was determined in parallel by means of a Mouse IgG1 ELISA Kit (Life Diagnostics, USA).
Results and Discussion
Biofunctionalization of PLLA with the purpose to enable VEGF delivery was achieved via physical adsorption, physical entrapment within a PAA hydrogel and covalent attachment via a hydrolysable bond. The observed release profiles evidence fastest release rate from the hydrogel, medium release rate of adsorbed VEGF and slowest release rate of the covalently attached VEGF (Fig. 2) . The release of physically adsorbed or entrapped VEGF is diffusion-controlled and starts immediately after insertion into the elution medium. Chemical attachment however affords the cleavage of covalent bonds prior to liberation of biomolecules. This was achieved in the case of VEGF by the formation of ester bonds between the side chain hydroxyl groups of VEGF and the DSC-activated surface amino groups. The applied biofunctionalization with CD34-Ab aimed in contrast at a non-cleavable chemical attachment by formation of stable amide bonds. This long-term immobilization could be evidenced by the absence of released CD34-Ab within the elution medium (Fig. 3) . However, we nevertheless observed a loss in CD34-Ab surface density after 3 days. This loss could be dedicated to CD34-Ab degradation under the chosen experimental conditions (37 °C, PBS).
Conclusion
In dependence of the applied immobilization protocol a short-term or long-term localization of biomolecules to biodegradable PLLA surfaces could be demonstrated. Biofunctionalization strategies should be hence thoroughly adapted to each envisaged application and offer numerous possibilities with regard to controlled drug release and surface functionality.
